AmoyDx(SZ:300685) 光大证券研究·2025-07-30 23:06Core Viewpoint - The company reported strong financial performance in the first half of 2025, with significant growth in net profit and a stable revenue increase, indicating robust operational capabilities and market position [2][3]. Financial Performance - In H1 2025, the company achieved revenue of 579 million yuan, a year-on-year increase of 6.69% [2]. - The net profit attributable to shareholders reached 189 million yuan, reflecting a substantial growth of 31.41% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 185 million yuan, up 39.97% year-on-year [2]. Product Performance - The core business of diagnostic reagents generated revenue of 483 million yuan, a year-on-year increase of 7.93%, accounting for 83.4% of total revenue with a gross margin of 90.72% [3]. - Revenue from testing services was 32.5 million yuan, a slight increase of 0.92%, with a gross margin of 48.66% [3]. - Revenue from drug clinical research services was 56.99 million yuan, down 5.00% year-on-year, with a gross margin of 53.14% [3]. Regional Sales - Domestic sales amounted to 442 million yuan, growing by 7.11% year-on-year [3]. - International sales and pharmaceutical business revenue reached 137 million yuan, an increase of 5.36% year-on-year [3]. R&D and Product Pipeline - The company invested 90.53 million yuan in R&D, representing 15.63% of total revenue, ensuring technological leadership [4]. - The company obtained 2 new Class III medical device registration certificates, bringing the total to 32, indicating a comprehensive and industry-leading product range [4]. - Five products, including human homologous recombinant repair defect detection kits, are in the review stage, with three included in innovation or priority approval processes [4]. International Expansion - The company has established partnerships with major pharmaceutical companies like AstraZeneca, Eli Lilly, Johnson & Johnson, and Pfizer for companion diagnostics [5]. - An international business team covering over 60 countries and regions has been established, indicating ongoing efforts in overseas expansion [5].